VectivBio Holding, a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, has announced the pricing of a USD 125 m underwritten offering of ordinary shares. The underwritten offering consists of 16,700,000 ordinary shares at